BIO89-100, a novel glycopegylated FGF21 analogue, demonstrates robust reduction in serum lipids and long half-life in a phase 1 randomized, controlled single ascending dose trial in healthy subjects

Authors
Category Primary study
JournalHepatology v70 suppl.1 2019
Year 2019
This article has no abstract
Epistemonikos ID: 5ad1b0dfa99e806501ea194bfd753dc69bf9fc20
First added on: Feb 11, 2025